Lab-on-a-chip to detect spread of pancreatic cancer in five hours

April 10, 2014 by Egoitz Gago

(Medical Xpress)—90% of cancer deaths are caused by metastasis. This occurs when a tumor sheds circulating tumor cells (CTC), which can invade new areas of the body. The process for detecting these cells is currently long, complex and expensive.

However, the European authorities believe it could be reduced as regards cost, time and human resources by using existing microfluidics technologies, and the CANDO project has been set up as a result. It will involve the work of the Basque technology centre IK4-IKERLAN and will consist of developing a lab-on-a-chip device to automatically identify and measure the concentration of CTCs.

This system will be used to predict, classify and monitor pancreatic cancer status, and early estimates suggest diagnosis will be available in just 5 hours. Detecting the cancer's progression will help assess individual response to oncological therapies (i.e. confirm whether the treatment is working or not), helping improve patients' quality of life.

Pancreatic cancer has a major socio-economic impact, as it is generally detected at a very advanced stage, with 96% mortality probabilities, in around 68,000 Europeans every year.

The laboratory procedures for detecting CTCs are difficult, time-consuming and expensive, as they are complicated by the low number of these cells in the bloodstream (around 1:1000000000). The analysis is conducted by a team of people and takes several days, involving manual sample extraction, identification and enumeration of the cells under the microscope and biological and molecular characterisation of the CTCs.

Apart from automation of the process, reducing its cost and speeding up , there is also a second aspect to the CANDO project: progress in 'targeted therapies', a type of treatment whose effects specifically focus on cells, causing very little damage to normal cells.

The advances achieved by the CANDO project will not only be used to predict, classify and monitor the status of but also to develop new, less invasive drugs to treat it.

How it works

The diagnosis procedure will consist of firstly taking a blood sample from the patient and placing it on a chip with micro-nano-bio and photonic systems able to amplify DNA and perform molecular analysis. The chip is then placed in the system created by IK4-IKERLAN for identifying and counting the CTCs. Five hours later the diagnosis is ready.

Although there is no date planned as yet for marketing the system, the CANDO project already has its own exploitation committee to guarantee its market introduction.

A marketing plan will be developed, mainly for Europe and the US. One of the first stages of the plan will include publicising the system at oncologists' meetings held by the European Society for Medical Oncology and at the European and American clinical oncology associations.

Explore further: New research may point to better predictor of prostate cancer survival

Related Stories

New research may point to better predictor of prostate cancer survival

March 21, 2014
New research by USC Norris Comprehensive Cancer Center scientists demonstrates that measuring circulating tumor cells (CTCs) – the cells that spread cancer through the body – may be a better predictor of patient survival ...

Capturing live tumor cells in the blood

August 8, 2013
Tumor cells circulating within a patient's bloodstream can carry cancer from a primary tumor site to distant sites of the body, spreading the disease.

Researchers identify potential treatment target for metastatic pancreatic cancer using CTC chip technology

July 30, 2012
(Medical Xpress) -- Researchers with the Stand Up To Cancer CTC Chip Dream Team have identified a potential treatment target in metastatic pancreatic cancer through a detailed analysis of genes expressed in circulating tumor ...

Detecting circulating tumor cells

March 25, 2013
A proof-of-concept device is nearly perfect in separating breast cancer cells from blood.

Third-generation device significantly improves capture of circulating tumor cells

April 3, 2013
A new system for isolating rare circulating tumor cells (CTCs) – living solid tumor cells found at low levels in the bloodstream – shows significant improvement over previously developed devices and does not require prior ...

DNA shed by tumors shows promise for non-invasive screening and prognosis

March 6, 2014
(Medical Xpress)—Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are ...

Recommended for you

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

How CD44s gives brain cancer a survival advantage

July 19, 2017
Understanding the mechanisms that give cancer cells the ability to survive and grow opens the possibility of developing improved treatments to control or cure the disease. In the case of glioblastoma multiforme, the deadliest ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.